-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi Announces Chinese Approval Of Tzield As First Disease-Modifying Therapy For Adult And Pediatric Patients With Stage 2 T1D

Benzinga·09/10/2025 06:22:05
Listen to the news
  • Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
  • Approval based on the TN-10 study, demonstrating Tzield's ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placebo
  • Additional regulatory reviews are ongoing across different disease stages by regulatory authorities around the world